The BA.3.2 (Cicada) variant is a recently identified subvariant of COVID-19 that has drawn attention due to its high number of mutations. As the virus continues to evolve, new variants like Cicada raise questions about transmission, symptoms, and vaccine effectiveness. Early reports suggest that this variant may behave differently from previous strains, although research is still ongoing. Health authorities are closely monitoring its spread and potential impact. Understanding emerging variants is essential for staying informed and protected.

Key Takeaways

  • 3.2 (Cicada) is a newly identified COVID-19 variant with a high number of mutations.
  • It may spread more easily, but current data is still being evaluated.
  • Standard precautions and vaccination remain key to protection.

What is the BA.3.2 (Cicada) Variant?

BA.3.2, also known as the Cicada variant, is a sublineage of the Omicron variant of COVID-19. It has been identified through genomic surveillance and stands out due to a large number of mutations, particularly in the spike protein. These mutations may influence how the virus spreads and interacts with the immune system. Like other Omicron-related variants, it is expected to be highly transmissible. However, its exact behavior and severity are still under investigation.

What are the Symptoms of BA.3.2 (Cicada)?

Symptoms of the BA.3.2 variant appear to be similar to other Omicron subvariants. Most cases are associated with mild to moderate respiratory symptoms. However, symptoms may vary depending on individual health and immunity levels. Monitoring symptoms early can help reduce transmission.

Common symptoms include:

  • Sore throat
  • Runny or blocked nose
  • Cough
  • Fatigue
  • Headache
  • Fever
  • Muscle aches

If you want to better understand how different COVID-19 variants present, you can also check our in-depth content on variants like Nimbus and Stratus.

What Makes BA.3.2 Different?

The BA.3.2 (Cicada) variant is notable for its unusually high number of mutations compared to earlier variants. Some reports suggest it may carry dozens of genetic changes, which could potentially affect transmissibility and immune response. Variants with multiple mutations are often monitored closely because they may behave differently. However, having more mutations does not always mean the variant is more dangerous. Further research is needed to understand its full impact.

How Does BA.3.2 Spread?

Like other COVID-19 variants, BA.3.2 spreads mainly through respiratory droplets and close contact. It can be transmitted when an infected person coughs, sneezes, or talks. The variant may spread more easily due to its mutations, but this is still being studied. Preventive measures remain important to reduce transmission.

Common transmission routes include:

  • Close contact with infected individuals
  • Airborne droplets in crowded or indoor environments
  • Contaminated surfaces

Is BA.3.2 More Dangerous?

At this stage, there is no clear evidence that the BA.3.2 variant causes more severe illness than previous Omicron variants. Most reported cases involve mild to moderate symptoms. However, individuals with weakened immune systems or underlying conditions may still be at higher risk. Ongoing research will provide more clarity about its severity and risks.

How is BA.3.2 Diagnosed?

BA.3.2 infection is diagnosed using standard COVID-19 testing methods. PCR tests and rapid antigen tests can detect the virus, although genomic sequencing is required to identify the specific variant. Testing remains an important tool for controlling the spread of COVID-19. Early detection helps guide isolation and treatment.

Diagnostic methods include:

  • PCR testing
  • Rapid antigen tests
  • Genomic sequencing 

What’s the Treatment for BA.3.2?

Treatment for BA.3.2 is similar to other COVID-19 variants. Most mild cases can be managed at home with rest and supportive care. Severe cases may require medical attention and hospitalization. Treatment approaches continue to evolve as more data becomes available.

Treatment options include:

  • Rest and hydration
  • Fever and pain management
  • Antiviral medications
  • Oxygen support in severe cases
  • Hospital care if complications develop

Can BA.3.2 Be Prevented?

Preventive measures remain the most effective way to reduce the spread of BA.3.2. Although variants may change, basic protection strategies continue to be effective. Vaccination also plays a key role in reducing severe illness. Maintaining awareness and following guidelines are essential.

Prevention tips include:

  • Get vaccinated and stay up to date with boosters
  • Wash hands regularly
  • Wear masks in crowded or high-risk areas
  • Avoid close contact with infected individuals
  • Ensure proper ventilation in indoor spaces

Which department should I visit?

Patients with COVID-19 symptoms should consult the Infectious Diseases or Pulmonology department. Specialists can evaluate symptoms and provide appropriate treatment when necessary.

Categories

Biochemistry Laboratory Bone Marrow Transplantation Cardiology Cardiovascular Surgery Check-up Child Psychology Dermatology Ear Nose and Throat ( ENT ) Endocrinology and Metabolic Diseases Gastroenterology General Surgery Gynecological Oncology Gynecology and Obstetrics Hematology Home Health (Care) Services In Vitro Fertilization (IVF) Infectious Diseases Internal Diseases Medical Biochemistry Medical Genetics Medical Oncology Nephrology Neurology Neurosurgery Nuclear Medicine Nutrition and Diet Ophthalmology Oral and Dental Health Organ Transplant Orthopedics and Traumatology Pediatric Allergy and Immunology Pediatric Cardiology Pediatric Cardiovascular Surgery Pediatric Hematology & Oncology Pediatric Neurology Pediatric Surgery Pediatrics Perinatology "High Risk Pregnancies" Physical Therapy and Rehabilitation Plastic Surgery Psychiatry Psychology Pulmonology Radiation Oncology Radiology Rheumatology Speech and Language Therapy Thoracic Surgery Urology View All

Frequently Asked Questions About BA.3.2 (Cicada)

Yes, BA.3.2 (Cicada) is a newly identified subvariant of the Omicron lineage that is currently being monitored by health authorities.

It may spread more easily due to its mutations, but more research is needed to confirm its transmissibility.

Vaccines are expected to continue providing protection against severe illness, although effectiveness against infection may vary.

If you experience symptoms, you should get tested, isolate if necessary, and follow medical advice.

There is currently no clear evidence that it causes more severe disease, but studies are ongoing.

Early data suggests that BA.3.2 may spread easily due to its high number of mutations, particularly in the spike protein. However, experts state that it does not yet show a clear growth advantage over other circulating variants. More research is needed to confirm its transmissibility.

The BA.3.2 (Cicada) variant has an unusually high number of mutations, with reports suggesting over 70 changes in the spike protein alone. These mutations are one of the main reasons it is being closely monitored by global health authorities.

No, BA.3.2 is currently classified as a “variant under monitoring” rather than a variant of concern. This means it is being observed for potential risks but has not shown clear evidence of increased severity or danger.

Some mutations in BA.3.2 may allow partial immune escape, meaning it could reduce protection against infection. However, current vaccines are still expected to provide strong protection against severe illness and hospitalization.

Current evidence shows that BA.3.2 does not cause more severe illness compared to other Omicron variants. Most cases remain mild to moderate, with symptoms similar to previous COVID-19 strains.

BA.3.2 has been identified in multiple countries and regions, including the United States and parts of Europe. It has spread across several states and continues to be monitored globally.

As with other COVID-19 variants, older adults, people with chronic conditions, and those with weakened immune systems are at higher risk of severe illness. Vulnerable groups should continue to take precautions and stay up to date with vaccinations.

Yes, like other Omicron subvariants, BA.3.2 may increase the risk of reinfection due to its mutations. Prior infection or vaccination may not fully prevent infection but can reduce severity

Medicana Web and Editorial Board

Created at

06.04.2026 12:52

Updated at

06.04.2026 01:01

Creator

Medicana Web and Editorial Board